Desensitization to lenalidomide in a patient with relapsed multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 162-165

  Seki, Jack T ^a,b   Banglawala, Sabiha ^a   Lentz, Emily M ^c   Reece, Donna E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DRAKE UNIVERSITY   (United States)

Author keywords

Drug desensitization; Lenalidomide; Multiple myeloma

Indexed keywords

ACICLOVIR; AMLODIPINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCUSATE SODIUM; DOXORUBICIN; FOSINOPRIL; GRANISETRON; LENALIDOMIDE; MELPHALAN; METFORMIN; METOPROLOL; OXYCODONE; PAMIDRONIC ACID; RANITIDINE; VINCRISTINE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CORTICOSTEROID THERAPY; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRURITUS; URTICARIA;

ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84877315463     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.09.003     Document Type: Article

References (20)

1. Revlimid (lenalidomide) capsules [prescribing information] 2010 Celgene Corporation Summit, NJ
2. H.P. Sviggum, M.D. Davis, S.V. Rajkumar Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma Arch Dermatol 142 2006 1298 1302 (Pubitemid 44583279)
3. R.A. Sharma, W.P. Steward, C.A. Daines Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies Eur J Cancer 42 2006 2318 2325 (Pubitemid 44307625)
4. K.V. Rao Lenalidomide in the treatment of multiple myeloma Am J Health Syst Pharm 64 2007 1799 1807 (Pubitemid 350202211)
5. J.D. Tariman Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma Clin J Oncol Nurs 11 2007 569 574
6. J.B. De Sanctis, M. Mijares, A. Suárez Pharmacological properties of thalidomide and its analogues Recent Pat Inflamm Allergy Drug Discov 4 2010 144 148
7. E. Nucera, D. Schiavino, S. Hohaus Desensitization to thalidomide in a patient with multiple myeloma Clin Lymphoma Myeloma 8 2008 176 178
8. K.C. Miller, L. Musial, A. Whitworth Management of patients with chronic lymphocytic leukemia treated with lenalidomide Clin J Oncol Nurs 14 2010 491 499
9. T. Nijsten, L. Meuleman, W. Schroyens Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone Dermatology 204 2002 365 367 (Pubitemid 34665172)
10. F. Gay, A. Palumbo Multiple myeloma: management of adverse events Med Oncol 27 2010 646 653
11. J. Phillips, J. Kujawa, M. Davis-Lorton Successful desensitization in a patient with lenalidomide hypersensitivity Am J Hematol 82 2007 1030 (Pubitemid 350004398)
12. C.P. Castaneda, N.A. Brandenburg, R. Bwire Erythema multiforme/Stevens- Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients J Clin Oncol 27 2009 156 157
13. Lenalidomide (marketed as Revlimid): serious skin reactions FDA drug safety newsletter: postmarketing reviews 1 2008 4 [serial online] http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm120613.htm Accessed: October 4, 2012
14. M.C. Castells, N.M. Tennant, D.E. Sloane Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases J Allergy Clin Immunol 122 2008 574 580
15. M.A. Riedl, A.M. Casillas Adverse drug reactions: types and treatment options Am Fam Physician 68 2003 1781 1790 (Pubitemid 37385772)
16. B.Y. Thong Clinical applications of drug desensitization in the Asia-Pacific region Asia Pac Allergy 1 2011 2 11
17. B.Y. Thong, C. Motala, T. Vervloet Drug Allergies. World Allergy Organization http://www.worldallergy.org/professional/allergic-diseases-center/ drugallergy Accessed: October 4, 2012
18. A. Giagounidis, P. Fenaux, G.J. Mufti Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes Ann Hematol 87 2008 345 352
19. J.R. Cernadas, K. Brockow, A. Romano General considerations on rapid desensitization for drug hypersensitivity - consensus statement Allergy 65 2010 1357 1366
20. M. Castells, MdelC. Sancho-Serra, M. Simarro Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization Cancer Immunol Immunother 61 2012 1575-18